Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 163

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 163
---
 exercise
of Series A warrants to purchase Class A Ordinary Shares (the “Series A Warrants”), (d) the exercise of Series B warrants
to purchase Class A Ordinary Shares (the “Series B Warrants”), (e) the exercise of Series C warrants to purchase Class A Ordinary
Shares (the “Exchange Warrants and together with the Series A Warrants, and the Series B Warrants, the “Warrants”),
and (f) the New CB Initial Note. We are registering the Resale Shares to satisfy certain registration rights that we have granted to the
Selling Securityholders.

The Selling Securityholders
may from time to time offer and sell any or all of the securities set forth below pursuant to this prospectus. When we refer to the “Selling
Securityholders” in this prospectus, we mean the persons listed in the tables below, and the pledgees, donees, transferees, assignees,
successors and others who later come to hold any of the Selling Securityholders’ interest in our securities after the date of this
prospectus.

The table below presents information
regarding the Selling Securityholders and the Resale Shares that they may offer from time to time under this prospectus. This table is
prepared based on information known to us as of August 21, 2025. The number of shares in the column “Maximum Number of Ordinary
Shares to be Sold Pursuant to this Prospectus” represents all of the Class A Ordinary Shares that the Selling Securityholders may
offer under this prospectus. The Selling Securityholders may sell some, all or none of its shares in this offering. We do not know how
long the Selling Securityholders will hold the shares before selling them, and we currently have no agreements, arrangements or understandings
with the Selling Securityholders regarding the sale of any of the shares.

Beneficial ownership is determined in accordance
with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes Class A Ordinary Shares with respect to which a Selling
Securityholder has voting and investment power. The percentage of Class A Ordinary Shares beneficially owned by the Selling Securityholder
prior to the offering shown in the table below is based on an aggregate of 2,152,702 Ordinary Shares outstanding as of August 21, 2025.
The fourth column assumes the sale of all of the shares offered by the Selling Securityholder pursuant to this prospectus.

The Company may require the
Selling Security